# Retraction: Abdallah MS, Mosalam EM, Hassan A, et al. Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial. CNS Neurosci. Ther. 2023;29:354–364 (https://doi.org/10.1111/cns.14010)

## TL;DR

This paper is a retraction of a study on using pentoxifylline to treat schizophrenia symptoms, due to concerns about data integrity.

## Contribution

The paper formally retracts a prior clinical trial, highlighting issues with data reliability and research integrity.

## Key findings

- The clinical trial's data was found to be unreliable.
- The retraction was agreed upon by the Editor-in-Chief and publisher.
- Confidence in the study's results was lost after an investigation.

## Abstract

Retraction: Abdallah MS, Mosalam EM, Hassan A, et al. Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial. CNS Neurosci. Ther. 2023;29:354–364 (https://doi.org/10.1111/cns.14010)

The above article, published online on November 07, 2022 in Wiley Online Library (wileyonlinelibrary.com) has been retracted by agreement between the journal's Editor‐in‐Chief, Xiaoming Hu, and John Wiley and Sons Ltd. Following publication, the Editor‐in‐Chief raised concerns about the integrity of the clinical trial. An investigation revealed significant issues regarding the reliability of the reported data. As a result, the Editor‐in‐Chief no longer has confidence in the validity of the results presented in this article.